

October 23, 2025

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku,
Tokyo
President & CEO: Osamu Okuda
Inquiries to: Kae Miyata
Head of Corporate Communications Dept.
Tel:
For media: +81-(0)3-3273-0881
For investors: +81-(0)3-3273-0554

F. Hoffmann-La Roche Announces Third Quarter Sales 2025

F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head Office: Basel, Switzerland. CEO: Thomas Schinecker] announced today its third quarter sales 2025 (January 1 – September 30, 2025).

Roche Holding Ltd, a parent company of Roche and Chugai, owns 59.89% of Chugai’s issued shares (61.11% of voting rights) as of the end of June 2025.

Its investor update and presentation materials can be found on its website (<https://www.roche.com>). Chugai’s performance for the period of January 1 to September 30, 2025 is included in the announced Roche Group’s results.

[Investor Updates](#)

[Reporting](#)

###